LifeMD Inc
NASDAQ:LFMD
LifeMD Inc
LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. The company is headquartered in New York City, New York and currently employs 232 full-time employees. The company went IPO on 2001-07-11. The firm's portfolio of brands is included within two operating segments: Telehealth and WorkSimpli. Its telehealth platform provides patients with access to licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis. In addition to its telehealth offerings, the Company sells complementary nutritional supplements and over-the-counter (OTC) products. Its products are available on a subscription basis, where patients can subscribe to receive regular shipments of prescribed medications or products. Its Shapiro MD brand offers products for male and female hair loss, OTC minoxidil, medical device, and a personalized telehealth platform. Rex MD is its men's brand, which offers access to provider-based treatment for erectile dysfunction, as well as treatment for other common men's health issues.
LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. The company is headquartered in New York City, New York and currently employs 232 full-time employees. The company went IPO on 2001-07-11. The firm's portfolio of brands is included within two operating segments: Telehealth and WorkSimpli. Its telehealth platform provides patients with access to licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis. In addition to its telehealth offerings, the Company sells complementary nutritional supplements and over-the-counter (OTC) products. Its products are available on a subscription basis, where patients can subscribe to receive regular shipments of prescribed medications or products. Its Shapiro MD brand offers products for male and female hair loss, OTC minoxidil, medical device, and a personalized telehealth platform. Rex MD is its men's brand, which offers access to provider-based treatment for erectile dysfunction, as well as treatment for other common men's health issues.
Growth: Revenue for 2025 was $194.1 million (up 25% year‑over‑year) and the company ended Q4 with over 322,000 active subscribers and strong momentum into 1Q26.
GLP‑1 Demand: Record demand for GLP‑1s, especially the oral Wegovy launch in January, with weight management new sign‑ups approaching 700/day and over 80% of new sign‑ups on branded therapy in early 2026.
Profitability Path: Adjusted EBITDA of $15.3 million for 2025; company expects an adjusted EBITDA loss of $4M–$5M in Q1 2026 (driven by marketing investment) and full‑year 2026 adjusted EBITDA of $12M–$17M with run‑rate targets of >$25M EBITDA and >$250M revenue by Q4.
Pharmacy & Fulfillment: Affiliate pharmacy is licensed in all 50 states, processing ~20,000 prescriptions/month, with in‑house fulfillment approaching 70% and early incremental margin lift of ~150–200 bps.
AI & Platform: Company is investing heavily in internal AI/engineering to deploy clinical decision support, personalized prescribing and automation across operations as a key differentiator.
New verticals: Major investment and launch of a virtual women's health offering (menopause, hormonal and bone health); early unit economics and retention look encouraging but still early.
Balance sheet & cash: $36.8 million in cash, no debt; management says they have the liquidity to make discretionary marketing investments to accelerate growth.
